CN107208107B - 伤口愈合的方法 - Google Patents

伤口愈合的方法 Download PDF

Info

Publication number
CN107208107B
CN107208107B CN201580070791.8A CN201580070791A CN107208107B CN 107208107 B CN107208107 B CN 107208107B CN 201580070791 A CN201580070791 A CN 201580070791A CN 107208107 B CN107208107 B CN 107208107B
Authority
CN
China
Prior art keywords
wound
lactic acid
seq
protein
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580070791.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107208107A8 (zh
CN107208107A (zh
Inventor
埃维利纳·威格斯乔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202110680754.6A priority Critical patent/CN113403244B/zh
Publication of CN107208107A publication Critical patent/CN107208107A/zh
Publication of CN107208107A8 publication Critical patent/CN107208107A8/zh
Application granted granted Critical
Publication of CN107208107B publication Critical patent/CN107208107B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0057—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Materials Engineering (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580070791.8A 2014-12-23 2015-12-23 伤口愈合的方法 Active CN107208107B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110680754.6A CN113403244B (zh) 2014-12-23 2015-12-23 伤口愈合的方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1451658-7 2014-12-23
SE1451658 2014-12-23
PCT/EP2015/081146 WO2016102660A1 (en) 2014-12-23 2015-12-23 Methods for wound healing

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110680754.6A Division CN113403244B (zh) 2014-12-23 2015-12-23 伤口愈合的方法

Publications (3)

Publication Number Publication Date
CN107208107A CN107208107A (zh) 2017-09-26
CN107208107A8 CN107208107A8 (zh) 2017-12-26
CN107208107B true CN107208107B (zh) 2021-07-09

Family

ID=55080095

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580070791.8A Active CN107208107B (zh) 2014-12-23 2015-12-23 伤口愈合的方法
CN202110680754.6A Active CN113403244B (zh) 2014-12-23 2015-12-23 伤口愈合的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110680754.6A Active CN113403244B (zh) 2014-12-23 2015-12-23 伤口愈合的方法

Country Status (9)

Country Link
US (3) US10696974B2 (enExample)
EP (2) EP3735979B1 (enExample)
JP (2) JP6581208B2 (enExample)
KR (2) KR102297619B1 (enExample)
CN (2) CN107208107B (enExample)
AU (2) AU2015370982B2 (enExample)
CA (1) CA2971520C (enExample)
ES (2) ES3048233T3 (enExample)
WO (1) WO2016102660A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3408378B1 (en) 2016-01-25 2022-01-12 NantCell, Inc. Nk cells with altered cxcl12/cxcr4 signaling
BR112019007812A2 (pt) * 2016-10-31 2019-07-16 Kimberly Clark Co métodos para arquivar e de recriar um microbioma.
CN110157733A (zh) * 2018-02-11 2019-08-23 四川大学 重组mIL-22BP载体、脂质体复合物及其制备方法和用途
CN117487686A (zh) * 2018-07-24 2024-02-02 生命大地女神有限公司 选择和使用褪黑素支持细菌以减少婴儿绞痛
MX2020014222A (es) * 2018-07-24 2021-03-09 Biogaia Ab Metodos terapeuticos que utilizan cepas bacterianas las cuales son capaces de aumentar los niveles de adenosina.
CN109112155A (zh) * 2018-08-02 2019-01-01 南昌大学 乳酸乳球菌mg1363的构建及其在治疗细菌性阴道炎中的应用
CN109517772A (zh) * 2018-10-30 2019-03-26 南昌大学 一种乳酸乳球菌mg1363的构建及其在治疗产妇乳头皲裂中的应用
CN109234298A (zh) * 2018-10-30 2019-01-18 南昌大学 一种卷曲乳杆菌atcc55221的构建及其在治疗产妇乳头皲裂中的应用
JP7045671B2 (ja) * 2018-11-12 2022-04-01 有限会社バイオ研 皮膚塗布用の皮膚創傷治癒促進組成物、その製造方法、及び創傷被覆材
US20230310522A1 (en) * 2019-06-24 2023-10-05 Mendes S.R.L. Composition with antibacterial and re-epithelializing action including probiotics
CN110623792B (zh) * 2019-09-23 2022-05-06 温州医科大学附属第一医院 一种医学敷料及其制备方法
CN114470007B (zh) * 2020-11-13 2024-10-18 葡萄王生技股份有限公司 含乳酸菌发酵产物之皮肤创伤外用组合物及其用途
CA3228922A1 (en) 2021-10-11 2023-04-20 Ajinomoto Co., Inc. Bacterium modified to express heterologous tat protein
WO2023118327A1 (en) 2021-12-22 2023-06-29 Ilya Pharma Ab Live bacteria as excipients for proteins
AU2022429649A1 (en) * 2021-12-29 2024-08-08 Ilya Pharma Ab Treatment of therapy-induced enteropathy
KR102752056B1 (ko) * 2023-07-12 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리(Lactobacillus reuteri) NCHBL-005 균주를 포함하는 창상 예방 또는 치료, 피부 재생 촉진용 조성물
GB202405882D0 (en) 2024-04-26 2024-06-12 Ilya Pharma Ab Treatment of mdr infections
CN118948906B (zh) * 2024-10-16 2025-02-14 温州医科大学附属第一医院 一种促进创面愈合的乳酸杆菌生物膜衍生物及其制备方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
WO1998035035A1 (fr) * 1997-02-07 1998-08-13 Shionogi & Co., Ltd. Nouveau recepteur de chimiokine cxc murin
AU781679B2 (en) 1999-07-05 2005-06-09 Intrexon Actobiotics Nv Delivery of trefoil peptides
CA2311201A1 (en) 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US7780961B2 (en) 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
WO2006124013A2 (en) * 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
WO2006018446A2 (en) 2004-08-20 2006-02-23 Actogenix Nv Method to improve lactococcus preservation
ES2626610T3 (es) 2005-08-30 2017-07-25 Intrexon Actobiotics Nv Bacterias de ácido láctico productoras del anti-TNF alfa para el tratamiento de la enfermedad inflamatoria intestinal
US20080254014A1 (en) 2005-10-03 2008-10-16 Actogenix N V Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US20110183348A1 (en) 2010-01-22 2011-07-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for therapeutic delivery with microorganisms
RU2008147398A (ru) 2006-05-02 2010-06-10 Актогеникс Н.В. (Be) Доставка пептидов, связанных с ожирением, через кишечник посредством микроорганизмов
CA2672229A1 (en) 2006-12-14 2008-06-19 Actogenix N.V. Delivery of binding molecules to induce immunomodulation
CA2673409A1 (en) 2006-12-19 2009-06-26 Ferrosan A/S Wound or tissue dressing comprising lactic acid bacteria
RU2009127718A (ru) 2006-12-19 2011-01-27 Ферросан А/С (Dk) Раневой или тканевой перевязочный материал, содержащий молочнокислые бактерии
EP3124614B1 (en) 2007-01-12 2022-06-08 Intrexon Actobiotics NV Lactococcus promoters and uses thereof
EP2774621B1 (en) 2007-01-25 2018-01-24 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
US20110044945A1 (en) * 2007-02-08 2011-02-24 Rappaport Family Institute For Research In The Medical Sciences Agents for the treatment of multiple sclerosis and methods of using same
WO2008155120A2 (en) 2007-06-20 2008-12-24 Actogenix Nv Methods and compositions for treating mucositis
US8435953B2 (en) 2007-11-07 2013-05-07 Yasuhiko Tabata Sustained release composition containing SDF-1
WO2009079451A2 (en) 2007-12-14 2009-06-25 The Cleveland Clinic Foundation Compositions and methods of promoting wound healing
US8367109B2 (en) 2008-04-09 2013-02-05 Brookhaven Science Associates, Llc Microbes encapsulated within crosslinkable polymers
EP2344626B1 (en) 2008-09-29 2017-03-29 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
US20100143305A1 (en) * 2008-12-08 2010-06-10 James Allen Lemke Treatment of hiv and aids using probiotic lactobacillus reuteri
WO2010123699A2 (en) 2009-04-21 2010-10-28 University Of Miami Compositions, kits and methods for promoting ischemic and diabetic wound healing
EP2243487A1 (en) 2009-04-23 2010-10-27 Actogenix N.V. Enteric coated formulation
WO2010124855A1 (en) 2009-04-30 2010-11-04 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
US20100310514A1 (en) * 2009-06-04 2010-12-09 Chi Hin Cho Anti-Inflammatory Bacteria
CL2009001506A1 (es) 2009-07-01 2009-09-25 Univ Concepcion Parche o aposito a base de hidrocoloides compuesto por una lamina de gelatina reticulada que comprende cepas viables probioticas productoras de acido lactico de lactobacillus acidophilus dsm 17371, un agente reticulante y un agente plastificante; y proceso para elaborar dicho parche.
US20120283315A1 (en) 2009-08-28 2012-11-08 Penn Marc S Sdf-1 delivery for treating ischemic tissue
EP3192873A1 (en) 2009-09-29 2017-07-19 Intrexon Actobiotics NV Lactobacillus and streptococcus promoters and uses thereof
GB2482536B (en) * 2010-08-05 2013-07-24 Hera Pharmaceuticals Inc Expression of antibody or a fragment thereof in lactobacillus
CN101985052B (zh) 2010-08-31 2013-11-06 中国人民解放军第二军医大学 自动捕获内皮祖细胞促进血管化的皮肤替代物及其构建方法
DK2704704T3 (en) 2011-05-03 2019-01-14 Dupont Nutrition Biosci Aps PROBIOTIC BACTERIES FOR TOPICAL TREATMENT OF SKIN DISORDERS
US9920324B2 (en) 2011-06-01 2018-03-20 Intrexon Actobiotics Nv Polycistronic expression system for bacteria
EP2758512B1 (en) 2011-09-23 2018-05-09 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
BR112014006883A8 (pt) 2011-09-23 2018-06-26 Actogenix Nv bactéria gram-positiva não patogênica carecendo de atividade do componente llc do sistema pts celobiose específico (ptcc), medicamento, aditivo alimentar, composição probiótica, ou cultura iniciadora, produto alimentar e métodos
GB201206599D0 (en) 2012-04-13 2012-05-30 Univ Manchester Probiotic bacteria
CN105263507A (zh) 2013-03-15 2016-01-20 尤文塔斯医疗公司 使用sdf-1减轻瘢痕形成
WO2014146202A1 (en) * 2013-03-18 2014-09-25 London Health Sciences Centre Research Inc. Bacteria for the prevention, treatment and diagnosis of breast cancer
HUE059749T2 (hu) 2013-04-29 2022-12-28 Medregen Llc Sebgyógyítás autológ õssejt-mobilizáció útján
WO2016124239A1 (en) 2015-02-04 2016-08-11 Aurealis Oy Recombinant probiotic bacteria for use in the treatment of a skin dysfunction

Also Published As

Publication number Publication date
WO2016102660A1 (en) 2016-06-30
US20230093013A1 (en) 2023-03-23
US20200299703A1 (en) 2020-09-24
AU2019204290A1 (en) 2019-07-04
JP2020005646A (ja) 2020-01-16
KR20170097194A (ko) 2017-08-25
AU2015370982B2 (en) 2019-03-21
CA2971520A1 (en) 2016-06-30
CN107208107A8 (zh) 2017-12-26
ES3048233T3 (en) 2025-12-09
EP3237622A1 (en) 2017-11-01
EP3237622B1 (en) 2021-02-24
ES2864373T3 (es) 2021-10-13
JP6581208B2 (ja) 2019-09-25
CN107208107A (zh) 2017-09-26
KR20200020994A (ko) 2020-02-26
EP3735979A1 (en) 2020-11-11
US11473091B2 (en) 2022-10-18
CN113403244A (zh) 2021-09-17
US20180187202A1 (en) 2018-07-05
KR102081493B1 (ko) 2020-02-26
JP7033109B2 (ja) 2022-03-09
EP3735979B1 (en) 2025-08-13
CA2971520C (en) 2024-04-09
KR102297619B1 (ko) 2021-09-02
EP3735979C0 (en) 2025-08-13
AU2015370982A1 (en) 2017-07-13
CN113403244B (zh) 2022-08-19
AU2019204290B2 (en) 2021-12-16
JP2018502600A (ja) 2018-02-01
US10696974B2 (en) 2020-06-30

Similar Documents

Publication Publication Date Title
CN107208107B (zh) 伤口愈合的方法
AU2015381262B2 (en) Recombinant probiotic bacteria
Huang et al. Modulation of macrophages by a phillyrin-loaded thermosensitive hydrogel promotes skin wound healing in mice
EP2687224A1 (en) Medicament for wound treatment
WO2023118327A1 (en) Live bacteria as excipients for proteins
HK1242736A1 (en) Methods for wound healing
HK1242736B (en) Methods for wound healing
JP2025139528A (ja) 抗菌剤
HK40061829A (en) Methods for wound healing
HK1240848B (en) Recombinant probiotic bacteria
HK1240848A1 (en) Recombinant probiotic bacteria
BR112017016772B1 (pt) Bactérias probióticas recombinantes

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application

Correction item: Inventor

Correct: Evelina Wigsjo

Correct: Evelina Wigsjo

False: Evelina Wigsjo|Mia Philipson|Russ Stefan

Number: 39-01

Number: 39-01

Volume: 33

Page: The title page

Correction item: Inventor

Correct: Evelina Wigsjo

False: Evelina Wigsjo|Mia Philipson|Russ Stefan

Number: 39-01

Volume: 33

GR01 Patent grant
GR01 Patent grant